|1.||Komatsu, Kazuto: 1 article (11/2002)|
|2.||Kontani, Hitoshi: 1 article (11/2002)|
|3.||Yokoyama, Osamu: 1 article (11/2002)|
|4.||Tanaka, Tomoko: 1 article (11/2002)|
|5.||Nakamura, Yasuo: 1 article (11/2002)|
|6.||Namiki, Mikio: 1 article (11/2002)|
|7.||Gambino, A: 1 article (04/2000)|
|8.||Thomas, B J: 1 article (04/2000)|
|9.||Wanstall, J C: 1 article (04/2000)|
|1.||Hypotension (Low Blood Pressure)
06/01/1997 - "The results of the present study show that KRN2391 is effective in reducing afterload during induced hypotension, and suggest that the hemodynamic profiles of KRN2391-induced hypotension are a hyperdynamic state as expressed by twofold increases in CI concomitant with the increase in right ventricular filling pressures. "
06/01/1997 - "The aim of this study was to investigate the potential use of KRN2391 for induced hypotension. "
06/01/1997 - "Hypotension induced by KRN2391 was associated with a 224% maximum increase (P<0.01) in cardiac index (CI) and a 136% maximum increase (P<0.01) in stroke volume index (SVI) during induced hypotension. "
09/01/1997 - "While both drugs were equally able of inducing hypotension, our results show that the haemodynamic profile of KRN2391- and nicardipine-induced hypotension was a hyperdynamic state expressed by the marked increase in cardiac index with varying changes in right and left ventricular filling pressures, and suggest that KRN2391 may be a useful vasodilator for induced hypotension."
06/01/1997 - "Possible evaluation of hemodynamic effects of the potassium channel opener KRN2391 on induced hypotension in dogs."
|2.||Myocardial Ischemia (Ischemic Heart Diseases)
07/01/1994 - "7. The pharmacological properties of KRN2391 are thought to be beneficial for the treatment of patients with ischemic heart disease."
07/01/1992 - "Thus, KRN2391 may be useful to treat ischemic heart disease, because it increases the coronary blood flow and the oxygen supply to the heart, and decreases the afterload and the myocardial oxygen consumption."
|4.||Heart Diseases (Heart Disease)
02/16/1993 - "Thus, both KRN2391 and cromakalim have beneficial effects on biochemical parameters during ischemia and reperfusion, effects which may be related to cardiodepression during ischemia."
02/16/1993 - "Isolated buffer-perfused rat hearts pretreated with KRN2391, cromakalim and vehicle were subjected to 25 min of ischemia followed by 30 min of reperfusion. "
02/16/1993 - "The effects of two structurally different K+ channel openers, KRN2391 and cromakalim, on cardiac mechanisms during ischemia and reperfusion were studied in isolated perfused rat hearts. "
11/05/1991 - "Before ischemia, KRN2391 (1-10 microM) and nicorandil (10-1000 microM) increased coronary flow, but did not modify the cardiac mechanical function. "
02/16/1993 - "During ischemia, KRN2391 (3, 10 microM) and cromakalim (10 microM) significantly accelerated the reduction in cardiac function and attenuated the decreased levels of ATP and ECP, but did not change the lactate content. "
|1.||Nicorandil (SG 75)
|4.||Adenosine Triphosphate (ATP)
|7.||Potassium Channels (Potassium Channel)